GS Asia Views: China's big ease continues

1. Chinese policymakers have stepped up the pace of easing in recent weeks, with interest rates continuing lower. The 7-day repo rate -- the key short-term policy interest rate -- has fallen nearly 300bp in just two months. Lower rates are typical following periods of rapid debt accumulation in most countries, as policymakers try to maintain growth by easing high debt service costs. With repo rates near our year-end forecast of 2.25% and the curve steepening through our target of 30bp, we see the best opportunities now further out the curve. Policymakers' focus may also have shifted in this direction, given their desire to ensure a successful launch of new municipal securities in coming weeks.

2. Heightened focus on supporting economic activity--reinforced at the most recent Politburo meeting--is clearly appropriate. Q1 growth was dismal, the worst since the global financial crisis. Official data implied only a 2-3% real GDP growth pace on a quarter-over-quarter basis after subtracting a large contribution from the financial sector's fervent activity, and industrial output was especially weak in March.

3. Lower rates are unlikely to be sufficient by themselves to push Chinese growth back up towards the official target of "around 7%". Measures to stabilize housing activity--recent data suggests that progress is being made in this area, although we saw a false start late in 2014--and especially to boost fiscal outlays will be key. On the latter point, local governments have been a key source of growth in China in recent years, generating significant revenue from land sales and borrowing heavily via off-balance sheet funding vehicles. With these revenue sources under threat--the former from a softer property market and the latter from regulatory intervention to bring greater accountability and transparency--and the anticorruption campaign providing strong incentives for local officials to be conservative, spending has slowed significantly.

4. Clients we visited recently in London, Singapore, Seoul, and Tokyo were extremely curious about the Chinese equity boom--even after the selloff of the past few days, A shares have rallied over 70% in 6 months--and what it means for the economy and other asset markets. We see a stronger equity market as a helpful, albeit modest, support for activity in the near term, and perhaps more importantly as a vehicle for reducing the reliance of the economy on debt financing. Our equity strategists remain overweight, though they see the best opportunities in offshore listings such as select H-shares and China ADRs. Views differ considerably depending on where clients sit, with sentiment bullish within greater China and generally more skeptical outside it.

5. Skepticism has certainly been the theme in southern Asian asset markets in recent weeks. Weakness in equities and some currencies (notably the Thai baht) began before the selloff in core bond markets--based on client conversations, this seems to reflect concerns about the progress of structural reforms, weaker-than-expected growth outcomes, and possibly some rotation towards China-related assets. Governments in south and southeast Asia are confronting diverse challenges, including pressure to deliver on high reform expectations and/or domestic political challenges. Though some political leaders in the region have openly called for monetary easing, central bankers remain concerned about various domestic (inflation or credit growth) or external (current account) imbalances despite progress since the "taper tantrum", particularly given expectations for the onset of Fed rate hikes later this year.

6. Indeed, a key concern raised in client meetings--particularly within Asia--continues to be the potential impact of Fed rate hikes on regional asset markets and currencies. For policymakers dealing with "lowflation" concerns, weaker currencies are more likely to be an acceptable or even desirable outcome of Fed tightening (for example in Japan, Korea, and Thailand--arguably China too, though policymakers there seem more focused on maintaining stability versus the dollar to support their longer-term policy goal of renminbi internationalization). For countries such as Indonesia (and to a lesser extent India) that run current account deficits, or for rate-sensitive financial centers such as HK and Singapore, a gradual Fed liftoff will be especially important.

7. From an investment perspective, we see the biggest opportunity for further policy rate cuts in China (where we expect a benchmark rate cut of 50bp), Korea, and Thailand. Further cuts are also a possibility in India (where the market is already pricing one) and Indonesia (given a disappointing Q1 growth report), though our base case in both countries is for policy to stay on hold. Our Japan economics team expects the Bank of Japan to step up monetary easing to maintain the credibility of the 2% inflation target; however, this now appears likely to happen later in the year (October is our forecast) given the BOJ recently revised its expected timeframe for achieving the target back to mid-2016. While the BOJ's adjustment appears to have been digested relatively well by markets (at least compared to recent European and US bond market moves), any signs of a more significant rethink in the policy approach might not be --though we emphasize this is a medium term risk, not a concern for the coming 12-18 months.

>>> InterXion options include counter-offer for Telecity

InterXion options include counter-offer for Telecity

Launching a counter-bid against Equinix [EQIX: NASDAQ] for Telecity [TCY:LON] is one of several responses InterXion [NYSE:INXN] will consider, it is understood.

Equinix launched on 7 May a non-binding offer for Telecity at GBP 11.45 per share, payable in cash and stock. Telecity had already agreed to acquire InterXion through an all-share merger announced in March.

In principle InterXion has the financial capabilities to outbid Equinix's current proposal and buy Telecity, it was said. At this stage, it is not clear whether such an offer would be made using cash and stock, it is understood. However, an all-cash bid partially funded using equity would be possible.

InterXion would find it difficult to compete if Equinix made a firm offer, it was said separately. Telecity and InterXion are of similar size, it was noted, and the cash portion of any competing offer would likely have to equal Equinix’s.

InterXion will also consider whether it should accept a reduced premium for its shares tendered to Telecity, it is understood.

The existing agreement would see InterXion shareholders receive 2.3386 new TelecityGroup shares per Interxion share. TelecityGroup shareholders will own approximately 55%, and InterXion shareholders approximately 45% in the combined entity.

The exchange ratio of 2.3386 new TelecityGroup shares per Interxion share implies a 15% premium.

A third option available would be to adjust the exchange ratio offering InterXion a smaller stake in the combined entity, it was said. InterXion’s priority is to pursue its deal with Telecity, it was said. Equinix’s approach nullifies the exclusivity obligation placed on Telecity and InterXion.

Alternative bidders for InterXion include Digital Realty, which has identified the European market as a priority, it was noted. The list of potential bidders in the data centre and colocation space is limited though, it was said.

Telecity shareholders have said they are very pleased with the potential Equinix offer, a source said. The company’s share price rose from 900p per share to GBP 10.93 since the deal announcement.

There are several factors that contribute to the attractiveness of a deal with InterXion, it was said. Firstly, the combination with InterXion has known synergies, while Equinix is yet to conduct due diligence on Telecity.

Shareholders taking a three-four year view on Telecity stock may favour a combination with InterXion, it was noted.

InterXion declined to comment while Telecity could not be reached.

(BFW) *TEVA SAID TO SEEK $25 BILLION IN FINANCING FOR MYLAN TAKEOVER


BN 05/08 16:37 *NO FINAL DECISION MADE ON RAISING OFFER PRICE ON MYLAN
BN 05/08 16:37 *TEVA TALKING TO BANKS INCL. BARCLAYS, CITI, BOFA, HSBC ON LOAN
BN 05/08 16:36 *TEVA FINANCING MAY GIVE IT MEANS TO RAISE MYLAN BID: SOURCES

*TEVA SAID TO SEEK $25 BILLION IN FINANCING FOR MYLAN TAKEOVER
2015-05-08 16:36:52.901 GMT

--ELIZABETH FOURNIER

-0- May/08/2015 16:36 GMT

>>> S&P lowers Turkey local currency sovereign rating one notch from BBB to BBB-



S&P lowers Turkey local currency sovereign rating one notch from BBB to BBB- (lowest level of investment grade); outlook Negative - affirms foreign currency sovereign ratings at BB+

The lowering of the local currency sovereign credit ratings on Turkey reflects what we consider to be increasing curbs on the operational independence of Turkey's central bank, which in our opinion have made it more challenging for the monetary authority to credibly fulfill its price stability mandate and to dampen the impact of exchange rate volatility on the economy's growth prospects. Another consequence of rising currency volatility, which reflects a less transparent monetary policy, is the re-dollarization of the financial sector's deposit base. Overall, we now consider that the challenged credibility of the central bank, including a weakened monetary transmission channel, has diminished the status of the Turkish lira as a reliable transactional currency; we think this poses greater risks to the refinancing of Turkey's considerable stock of external debt. While we consider that Turkey's relatively deep capital markets benefit its monetary flexibility, we view the complex monetary framework--with multiple interest rates and an unusually broad interest rate corridor--as relatively ineffective given the high pass-through of exchange rate depreciation into headline inflation.

(TechCrunch) Amazon’s Delivery Drones Could Find You Wherever You Are



Amazon’s Delivery Drones Could Find You Wherever You Are


Keurig CEO Blames Coffee Pod DRM For Falling Sales

Amazon’s delivery drone plans may have seemed more like a media stunt than a concrete vision back when it launched, but with active testing taking place in Canada and now, new details showing up in a patent application, things are getting real. The new proposed patent for an “Unmanned Aerial Vehicle Delivery System” (via BBC) contains some impressive revelations about Amazon’s proposed automated package transport plans.

For instance, the system would use location information shared by a package recipient’s smartphone to be able to zero in on their position and bring deliveries directly to them, regardless of whether they happen to be at home or somewhere else. You’d also be able to specific different locations as package destinations, giving you more flexibility about where to receive things depending on your schedule or needs at the exact time of delivery.

This would be a huge step up from the current situation in terms of convenience. At best, delivery services will call me the morning a package is set to arrive to provide a heads up, and let you modify your delivery day online. Being able to tweak it while the package is en route to match up with your exact plans hour-by-hour would take a lot of the unnecessary stress and worry out of the whole process.

Amazon’s patent also includes details around how it will use sensors, cameras, radar and more to guarantee the drones can land safely, and how it will monitor its path to avoid humans and other obstructions. But the key magic here, in terms of how the system would present an improvement for consumers as well as giving Amazon benefits vs. current old-school delivery methods, is that intelligent, adaptable route-shifting.

Of course, it also means Amazon will have to take extra precautions to ensure that it’s not easy for bad actors to manipulate drone routing to intercept packages. But if it does work, and work well, custom routing alone would change the face of ecommerce and consumer delivery.

(BUS) Monsanto Comments on Proposal for Syngenta



BFW 05/08 13:48 *MONSANTO CONFIRMED MADE PRIVATE PROPOSAL TO SYNGENTA’S BOARD
BN 05/08 13:48 *MONSANTO:CONFIDENT IN ABILITY TO GET ALL REGULATORY APPROVALS
BN 05/08 13:46 *MONSANTO SAYS COMBINATION WOULD DELIVER SIGNIFICANT VALUE
BN 05/08 13:46 *MONSANTO CONFIDENT IN ABILITY TO OBTAIN NECESSARY REG APPROVALS
BN 05/08 13:46 *MONSANTO CONFIRMS PROPOSAL TO SYNGENTA’S BOARD
BN 05/08 13:46 *MONSANTO CONFIRMED PROPOSAL FOR 449.00 CHF/SHR
BN 05/08 13:46 *MONSANTO CONFIRMED MADE PRIVATE PROPOSAL TO SYNGENTA’S BOARD
BN 05/08 13:46 *MONSANTO COMMENTS ON PROPOSAL FOR SYNGENTA

Monsanto Comments on Proposal for Syngenta
2015-05-08 13:46:00.135 GMT

Monsanto Comments on Proposal for Syngenta

Business Wire

ST. LOUIS -- May 8, 2015

In response to Syngenta’s [VTX: SYNN] announcement this morning, Monsanto
Company [NYSE:MON] today confirmed that it had made a private proposal to
Syngenta’s Board of Directors to acquire Syngenta for 449.00 CHF per share.
The proposal contemplates consideration of approximately 45% cash and would
provide Syngenta shareholders with a very attractive premium and significant
further value creation through ongoing ownership in the combined company.

Monsanto has long respected and followed Syngenta’s business and believes
combining the two companies would deliver significant value to all
stakeholders, including shareholders. Creating a new company from the
combination of Syngenta’s strengths and leadership in crop protection
chemicals and Monsanto’s leadership in seeds, traits and information
technology would form an integrated global leader in agriculture with
comprehensive and complementary product portfolios, and an Ag-focused
organization with enhanced abilities to develop and accelerate innovative
solutions for growers. Monsanto believes the combined company would be
uniquely positioned to deliver a comprehensive suite of integrated solutions
to farmers around the world and to accelerate technological innovation through
precision agriculture and advanced research and development capabilities aimed
at increasing the world’s food supply in a sustainable fashion.

Monsanto believes a combination would deliver significant value to
shareholders of both companies. The combination is expected to result in
substantial synergies as the company delivers more integrated solutions to
customers.

Monsanto, in conjunction with its financial and legal advisors, has devoted
significant time and resources to analyzing a potential combination of
Syngenta and Monsanto and is confident in its ability to obtain all necessary
regulatory approvals.

Monsanto does not intend to make any additional comments on this matter at
this time.

About Monsanto Company

Monsanto is committed to bringing a broad range of solutions to help nourish
our growing world. We produce seeds for fruits, vegetables and key crops –
such as corn, soybeans, and cotton – that help farmers have better harvests
while using water and other important resources more efficiently. We work to
find sustainable solutions for soil health, help farmers use data to improve
farming practices and conserve natural resources, and provide crop protection
products to minimize damage from pests and disease. Through programs and
partnerships, we collaborate with farmers, researchers, nonprofit
organizations, universities and others to help tackle some of the world’s
biggest challenges. To learn more about Monsanto, our commitments and our more
than 20,000 dedicated employees, please visit: discover.monsanto.com and
monsanto.com. Follow our business on Twitter® at twitter.com/MonsantoCo, on
the company blog, Beyond the Rows® at monsantoblog.com or subscribe to our
News Release RSS Feed.

Cautionary Statements Regarding Forward-Looking Information:

Certain statements contained in this release are “forward-looking statements,”
such as statements concerning the anticipated financial results, current and
future product performance, regulatory approvals, business and financial plans
of the company and the potential combined business of the company and
Syngenta, including the expected benefits of a potential combination as well
as whether a potential combination will be entered into or completed, and
other non-historical facts. These statements are based on current expectations
and currently available information. However, since these statements are based
on factors that involve risks and uncertainties, the company’s actual
performance and results may differ materially from those described or implied
by such forward-looking statements. Factors that could cause or contribute to
such differences include, among others: continued competition in seeds, traits
and agricultural chemicals; the company’s exposure to various contingencies,
including those related to intellectual property protection, regulatory
compliance and the speed with which approvals are received, and public
acceptance of biotechnology products; the success of the company’s research
and development activities; the outcomes of major lawsuits and the
previously-announced SEC investigation; developments related to foreign
currencies and economies; successful operation of recent acquisitions;
fluctuations in commodity prices; compliance with regulations affecting the
company’s manufacturing; the accuracy of the company’s estimates related to
distribution inventory levels; the recent increases in and expected higher
levels of indebtedness; the company’s ability to fund its short-term financing
needs and to obtain payment for the products that it sells; the effect of
weather conditions, natural disasters and accidents on the agriculture
business or the company’s facilities; the possibility that a potential
transaction involving Syngenta will not be entered into or will be pursued on
different terms and conditions, failure to obtain necessary regulatory
approvals or to satisfy any of the other conditions to a possible transaction,
failure to realize the expected benefits thereof, or the impact of changes in
business, financial, market, legal or other conditions; and other risks and
factors detailed in the company’s most recent periodic report to the SEC.
Undue reliance should not be placed on these forward-looking statements, which
are current only as of the date of this release. The company disclaims any
current intention or obligation to update any forward-looking statements or
any of the factors that may affect actual results.

Contact:

Monsanto Company
Media:
Sara Miller, 314-694-5824
or
Analysts:
Laura Meyer, 314-694-8148
or
Joele Frank, Wilkinson Brimmer Katcher
Steve Frankel or Scott Bisang, 212-355-4449

-0- May/08/2015 13:46 GMT

>>> US Gapping down


Gapping down
In reaction to disappointing earnings/guidance
: AMDA -27.9%, KEYW -21.7%, FLDM -17.2%, PLNR -15.2%, TWOU -14.2%, BEBE -12.3%, BIOS -11.6%, POZN -8.7%, DXPE -8.5%, ABTL -8.4%, UBNT -8.3%, AVNW -7.9%, AVID -7.4%, MDVN -6.7%, MNST -6%, CNCE -5.1%, SPPI -4.9%, PSIX -4.8%, NVDA -4.1%, LIVE -3.5%, JD -3.3%, BBOX -3.1%, CST -3%, NOG -2.9%, CA -2.7%, JAZZ -2.5%, (Concert Pharmaceuticals and Jazz Pharmaceuticals (JAZZ) report results from their Phase 1 clinical study of JZP-386; studies do not support advancing into a later-stage clinical trial of JZP-386 at this time ), EGY -1.9%, TGI -1.9%, UEPS -1.8%, CERN -1.7%, WAIR -1.6%, TESO -1.6%, CROX -1.4%, MACK -1.3%, FATE -1.3%, HZNP -1.3%, CNTY -0.8%, HTGC -0.7%, STON -0.7%, NVAX -0.6%,

M&A news: CRM -3.5% (Microsoft (MSFT) not considering bid for CRM, according to Reuters)

Other news: LJPC
-9.7% (announces it will discontinue development of its polysaccharide-based galectin-3 inhibitors, GCS-100 and LJPC-1010),
ALDX -6.2% (prices its follow-on public offering of 2,700,000 shares of its common stock at $7.50 per share), CNCE -5.1% (Concert Pharmaceuticals and Jazz Pharmaceuticals (JAZZ) report results from their Phase 1 clinical study of JZP-386; studies do not support advancing into a later-stage clinical trial of JZP-386 at this time ), HMTV -3.1% (prices secondary public offering of ~3.2 mln shares of Class A common stock at $12 per share), CEMP -1.6% (filed mixed securities shelf offering), TSLA -1.2% (small pull back from recent strength), SMLP -0.9% (priced public offering of 6.5 mln common units at $30.75 per unit)

Analyst comments: MHR -1.1% (downgraded to Neutral from Buy at Citigroup), TWO -0.8% (downgraded to Mkt Perform from Outperform at Keefe